<DOC>
	<DOCNO>NCT00163332</DOCNO>
	<brief_summary>The aim study investigate effect ciclesonide versus fluticasone propionate versus placebo airway hyperresponsiveness hypothalamic-pituitary-adrenal axis ( HPA axis ) . Treatment medication administer follow : ciclesonide fluticasone propionate inhale twice daily , use one two dose level . The study duration consist baseline period ( 4 6 week ) , five treatment period ( 9 day ) , washout period treatment ( 4 12 week ) . The study provide data safety tolerability ciclesonide .</brief_summary>
	<brief_title>Effect Inhaled Ciclesonide Versus Fluticasone Propionate Patients With Mild Moderate Asthma ( 18 65 ) ( BY9010/M1-129 )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Main Patients history bronchial asthma least 6 month FEV1 &gt; 60 % predict least 24 h Patients hyperresponsive methacholine AMP Patients good health exception asthma Main Concomitant severe disease disease contraindication use inhaled steroid Patients suffer COPD and/or relevant lung diseases except asthma Current smoker exsmokers â‰¥10 pack year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Ciclesonide</keyword>
	<keyword>Fluticasone propionate</keyword>
</DOC>